Published in N Engl J Med on September 30, 2010
Combination Chemotherapy in Treating Children With Neuroblastoma | NCT00003093
Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell (2012) 5.44
Challenging issues in pediatric oncology. Nat Rev Clin Oncol (2011) 1.56
Clinical significance of tumor-associated inflammatory cells in metastatic neuroblastoma. J Clin Oncol (2012) 1.37
Neuroblastoma: molecular pathogenesis and therapy. Annu Rev Med (2014) 1.21
Advances in Risk Classification and Treatment Strategies for Neuroblastoma. J Clin Oncol (2015) 1.19
Mechanisms of neuroblastoma regression. Nat Rev Clin Oncol (2014) 1.17
Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable/disseminated neuroblastoma (a SIOPEN collaborative study). Br J Cancer (2011) 1.09
Exosome-mediated transfer of microRNAs within the tumor microenvironment and neuroblastoma resistance to chemotherapy. J Natl Cancer Inst (2015) 1.09
Advances in the translational genomics of neuroblastoma: From improving risk stratification and revealing novel biology to identifying actionable genomic alterations. Cancer (2015) 1.01
Neuroblastoma. Semin Pediatr Surg (2012) 0.97
Secondary leukemia associated with the anti-cancer agent, etoposide, a topoisomerase II inhibitor. Int J Environ Res Public Health (2012) 0.96
Outcome after surgery alone or with restricted use of chemotherapy for patients with low-risk neuroblastoma: results of Children's Oncology Group study P9641. J Clin Oncol (2012) 0.92
Subsequent malignant neoplasms in pediatric patients initially diagnosed with neuroblastoma. J Pediatr Hematol Oncol (2015) 0.91
Evaluation of Norepinephrine Transporter Expression and Metaiodobenzylguanidine Avidity in Neuroblastoma: A Report from the Children's Oncology Group. Int J Mol Imaging (2012) 0.90
Prognostic value of the stage 4S metastatic pattern and tumor biology in patients with metastatic neuroblastoma diagnosed between birth and 18 months of age. J Clin Oncol (2011) 0.82
Advances in chimeric antigen receptor immunotherapy for neuroblastoma. Discov Med (2013) 0.79
Second malignancies in patients with neuroblastoma: the effects of risk-based therapy. Pediatr Blood Cancer (2014) 0.79
Diagnostic FDG and FDOPA positron emission tomography scans distinguish the genomic type and treatment outcome of neuroblastoma. Oncotarget (2016) 0.79
Factors associated with recurrence and survival length following relapse in patients with neuroblastoma. Br J Cancer (2016) 0.77
Neuroblastoma: issues in transplantation. Biol Blood Marrow Transplant (2012) 0.77
Genetic discoveries and treatment advances in neuroblastoma. Curr Opin Pediatr (2016) 0.77
Advances in paediatric cancer treatment. Transl Pediatr (2014) 0.76
Effect of sulfasalazine on human neuroblastoma: analysis of sepiapterin reductase (SPR) as a new therapeutic target. BMC Cancer (2015) 0.76
Clinical observations on chemotherapy curable malignancies: unique genetic events, frozen development and enduring apoptotic potential. BMC Cancer (2015) 0.76
Horner's Syndrome and Neuroblastoma: our family's odyssey with disorders of the sympathetic nervous system. ACS Chem Neurosci (2010) 0.75
Downregulation of c-Myc is involved in TLR3-mediated tumor death of neuroblastoma xenografts. Lab Invest (2016) 0.75
Neuroblastoma survivors are at increased risk for second malignancies: A report from the International Neuroblastoma Risk Group Project. Eur J Cancer (2016) 0.75
Hepatic metastatic disease in pediatric and adolescent solid tumors. World J Hepatol (2015) 0.75
The under reporting of recruitment strategies in research with children with life-threatening illnesses: A systematic review. Palliat Med (2016) 0.75
SIOP-PODC adapted risk stratification and treatment guidelines: Recommendations for neuroblastoma in low- and middle-income settings. Pediatr Blood Cancer (2015) 0.75
A multidisciplinary team care approach improves outcomes in high-risk pediatric neuroblastoma patients. Oncotarget (2016) 0.75
MIBG avidity correlates with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group. Pediatr Blood Cancer (2017) 0.75
A multiple testing procedure for clinical trials. Biometrics (1979) 26.80
Chronic health conditions in adult survivors of childhood cancer. N Engl J Med (2006) 19.97
Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol (1993) 10.87
Neuroblastoma. Lancet (2007) 10.61
Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science (1984) 9.64
Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med (1985) 7.79
The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol (2008) 6.66
Molecular biology of neuroblastoma. J Clin Oncol (1999) 6.54
Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med (2005) 4.92
Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas. J Natl Cancer Inst (1984) 4.01
Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol (1991) 3.16
The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. J Clin Oncol (2008) 2.94
Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma. N Engl J Med (1996) 2.66
Overall genomic pattern is a predictor of outcome in neuroblastoma. J Clin Oncol (2009) 2.21
Cellular DNA content as a predictor of response to chemotherapy in infants with unresectable neuroblastoma. N Engl J Med (1984) 2.09
Localized infant neuroblastomas often show spontaneous regression: results of the prospective trials NB95-S and NB97. J Clin Oncol (2008) 1.91
Successful treatment of stage III neuroblastoma based on prospective biologic staging: a Children's Cancer Group study. J Clin Oncol (1998) 1.88
Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas. Oncogene (1999) 1.79
Surgical risk factors in primary surgery for localized neuroblastoma: the LNESG1 study of the European International Society of Pediatric Oncology Neuroblastoma Group. J Clin Oncol (2005) 1.66
International neuroblastoma pathology classification for prognostic evaluation of patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group. Cancer (2001) 1.58
Locoregional control in infants with neuroblastoma: role of radiation therapy and late toxicity. Int J Radiat Oncol Biol Phys (2002) 1.53
Detection of N-myc gene amplification by fluorescence in situ hybridization. Diagnostic utility for neuroblastoma. Am J Pathol (1993) 1.50
Favorable biology and outcome of stage IV-S neuroblastoma with supportive care or minimal therapy: a Children's Cancer Group study. J Clin Oncol (2000) 1.44
Hearing loss, quality of life, and academic problems in long-term neuroblastoma survivors: a report from the Children's Oncology Group. Pediatrics (2007) 1.42
Biologic factors determine prognosis in infants with stage IV neuroblastoma: A prospective Children's Cancer Group study. J Clin Oncol (2000) 1.40
Review of image defined risk factors in localized neuroblastoma patients: Results of the GPOH NB97 trial. Pediatr Blood Cancer (2008) 1.36
Significance of chromosome 1p loss of heterozygosity in neuroblastoma. Cancer Res (1995) 1.30
Excellent outcome with reduced treatment for infants with disseminated neuroblastoma without MYCN gene amplification. J Clin Oncol (2009) 1.27
Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the Cardiology Committee of the Childrens Cancer Study Group. Pediatrics (1992) 1.22
Criteria for evaluation of disease extent by (123)I-metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force. Br J Cancer (2010) 1.19
Outcomes of children with intermediate-risk neuroblastoma after treatment stratified by MYCN status and tumor cell ploidy. J Clin Oncol (2005) 1.08
Genetic staging of unresectable or metastatic neuroblastoma in infants: a Pediatric Oncology Group study. J Natl Cancer Inst (1997) 1.05
Prognostic significance of age, MYCN oncogene amplification, tumor cell ploidy, and histology in 110 infants with stage D(S) neuroblastoma: the pediatric oncology group experience--a pediatric oncology group study. J Clin Oncol (1998) 1.01
Therapy-related acute myeloid leukemia following treatment with epipodophyllotoxins: estimating the risks. Med Pediatr Oncol (1994) 0.97
Localized resectable neuroblastoma: results of the second study of the Italian Cooperative Group for Neuroblastoma. J Clin Oncol (1995) 0.95
The surgical challenge of neuroblastoma. J Pediatr Surg (1994) 0.94
Event-free survival of children with biologically favourable neuroblastoma based on the degree of initial tumour resection: results from the Pediatric Oncology Group. Eur J Cancer (1997) 0.94
Results of pediatric oncology group protocol 8104 for infants with stages D and DS neuroblastoma. J Pediatr Hematol Oncol (1995) 0.90
Localised and unresectable neuroblastoma in infants: excellent outcome with primary chemotherapy. Neuroblastoma Study Group, Société Française d'Oncologie Pédiatrique. Med Pediatr Oncol (2001) 0.89
Dose-related nephrotoxicity of carboplatin in children. Br J Cancer (1999) 0.88
The influence of age on nephrotoxicity following chemotherapy in children. Br J Cancer Suppl (1992) 0.86
Cisplatin therapy in infants: short and long-term morbidity. Br J Cancer Suppl (1992) 0.83
Postoperative treatment of nonmetastatic visible residual neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol (1991) 0.83
Long-term renal and hearing toxicity of carboplatin in infants treated for localized and unresectable neuroblastoma: results of the SFOP NBL90 study. Pediatr Blood Cancer (2005) 0.81
Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science (2004) 18.84
Neuroblastoma. Lancet (2007) 10.61
Acute lymphoblastic leukaemia. Lancet (2008) 8.54
Identification of ALK as a major familial neuroblastoma predisposition gene. Nature (2008) 7.38
Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature (2008) 6.80
NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth. Proc Natl Acad Sci U S A (2006) 6.80
The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol (2008) 6.66
Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell (2002) 6.64
Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med (2010) 6.34
Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. Nature (2007) 5.65
A tissue-scale gradient of hydrogen peroxide mediates rapid wound detection in zebrafish. Nature (2009) 5.55
The pediatric preclinical testing program: description of models and early testing results. Pediatr Blood Cancer (2007) 5.28
Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study. J Clin Oncol (2009) 5.12
Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med (2005) 4.92
The genetic landscape of high-risk neuroblastoma. Nat Genet (2013) 4.71
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors. J Exp Med (2007) 4.59
Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res (2009) 4.53
Adjustment of genomic waves in signal intensities from whole-genome SNP genotyping platforms. Nucleic Acids Res (2008) 4.22
tp53 mutant zebrafish develop malignant peripheral nerve sheath tumors. Proc Natl Acad Sci U S A (2005) 4.15
Copy number variation at 1q21.1 associated with neuroblastoma. Nature (2009) 4.10
Notch 1 activation in the molecular pathogenesis of T-cell acute lymphoblastic leukaemia. Nat Rev Cancer (2006) 3.89
Chromosome 6p22 locus associated with clinically aggressive neuroblastoma. N Engl J Med (2008) 3.80
Slug antagonizes p53-mediated apoptosis of hematopoietic progenitors by repressing puma. Cell (2005) 3.73
Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study. Lancet Oncol (2013) 3.70
Detectable clonal mosaicism and its relationship to aging and cancer. Nat Genet (2012) 3.69
BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma. Curr Biol (2005) 3.68
Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma. Nat Genet (2012) 3.38
STAC: A method for testing the significance of DNA copy number aberrations across multiple array-CGH experiments. Genome Res (2006) 3.21
Resolution of inflammation by retrograde chemotaxis of neutrophils in transgenic zebrafish. J Leukoc Biol (2006) 3.21
Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. Cancer Res (2004) 3.20
Chk1 suppresses a caspase-2 apoptotic response to DNA damage that bypasses p53, Bcl-2, and caspase-3. Cell (2008) 3.15
Myc-induced T cell leukemia in transgenic zebrafish. Science (2003) 3.15
The use of zebrafish to understand immunity. Immunity (2004) 3.09
Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease. J Clin Oncol (2007) 3.08
Activating Notch1 mutations in mouse models of T-ALL. Blood (2005) 3.08
Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study. Lancet Oncol (2009) 3.07
High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. Blood (2009) 3.02
Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP). Pediatr Blood Cancer (2010) 2.99
The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. J Clin Oncol (2008) 2.94
ZNF423 is critically required for retinoic acid-induced differentiation and is a marker of neuroblastoma outcome. Cancer Cell (2009) 2.93
Interplay of pu.1 and gata1 determines myelo-erythroid progenitor cell fate in zebrafish. Dev Cell (2005) 2.89
Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification. J Natl Cancer Inst (2006) 2.79
A functional screen identifies miR-34a as a candidate neuroblastoma tumor suppressor gene. Mol Cancer Res (2008) 2.77
Molecular genetics of acute lymphoblastic leukemia. J Clin Oncol (2005) 2.74
Sparse representation and Bayesian detection of genome copy number alterations from microarray data. Bioinformatics (2008) 2.65
Activating FLT3 mutations in CD117/KIT(+) T-cell acute lymphoblastic leukemias. Blood (2004) 2.60
The majority of total nuclear-encoded non-ribosomal RNA in a human cell is 'dark matter' un-annotated RNA. BMC Biol (2010) 2.59
Neuroblastoma cells isolated from bone marrow metastases contain a naturally enriched tumor-initiating cell. Cancer Res (2007) 2.56
The requirement for cyclin D function in tumor maintenance. Cancer Cell (2012) 2.49
Slug, a highly conserved zinc finger transcriptional repressor, protects hematopoietic progenitor cells from radiation-induced apoptosis in vivo. Cancer Cell (2002) 2.48
Common variations in BARD1 influence susceptibility to high-risk neuroblastoma. Nat Genet (2009) 2.47
Effects of lethal irradiation in zebrafish and rescue by hematopoietic cell transplantation. Blood (2004) 2.46
Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number. Cancer Res (2006) 2.42
High-risk neuroblastoma treated with tandem autologous peripheral-blood stem cell-supported transplantation: long-term survival update. J Clin Oncol (2006) 2.40
Temozolomide in the treatment of high-grade gliomas in children: a report from the Children's Oncology Group. Neuro Oncol (2011) 2.39
Guidelines for imaging and staging of neuroblastic tumors: consensus report from the International Neuroblastoma Risk Group Project. Radiology (2011) 2.35
Gene expression signatures in MLL-rearranged T-lineage and B-precursor acute leukemias: dominance of HOX dysregulation. Blood (2003) 2.35
A fluorescence microplate cytotoxicity assay with a 4-log dynamic range that identifies synergistic drug combinations. Mol Cancer Ther (2007) 2.35
A new amyloid beta variant favoring oligomerization in Alzheimer's-type dementia. Ann Neurol (2008) 2.32
Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: a report from the National Wilms Tumor Study Group. J Clin Oncol (2005) 2.28
Nfil3/E4bp4 is required for the development and maturation of NK cells in vivo. J Exp Med (2009) 2.26
Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial. Lancet Oncol (2013) 2.25
Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in myeloid cell transformation. Nat Med (2006) 2.23